Flying Publisher   

The Book

Download
66 pages, PDF, 1.4 MB

Preface

1. BSK

2. The Amedeo Story

3. HIV.NET

4. HIV Medicine

5. Flying Publisher

6. Free Medical Information

7. Amedeo Textbook Awards

Perspectives


The Awards

Preface

Rationale

Awards

Rules and Conditions

Application

Books

Exclusive Sponsorship

Donations

 
We'll inform you

Privacy

About

Individual or commercial sponsors would have the following visibility:

1. A presentation page (please see below) will be displayed at Amedeo Challenge for two years (the year before the deadline and the year thereafter).

2. The sponsors would be mentioned in all email correspondence about the Amedeo Award and the final winner (>800,000 emails; see details in: Rationale, #9 - Textbook Awards will generate an extraordinary return on investment).

3. Textbooks and corresponding websites created as a result of the Amedeo Award would acknowledge the sponsor and include a link to his websites (see Rules and Conditions, #6C).

4. Finally, sponsors might establish a durable contact with the clinical and research groups that wrote and published the textbooks.

A presentation page of an invididual sponsor might include a personal history, current activities, future projects, and links to own websites (see example).

A presentation page of a commercial sponsor would typically include statements about missions, achievements, products, and links to own websites. Examples:

• XYZ Pharma Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives.

• ABCD Pharma Inc is a leading healthcare company active in the discovery, development, manufacture and marketing of novel healthcare solutions. Its products and services address prevention, diagnosis and treatment of diseases.

  ABCD Pharma Incis is the producer of DCBA, an xxx inhibitor which sustained serum concentrations for a entire month.

  In clinical trials versus UTXR® combination therapy with DCBA demonstrated superior efficacy. The recommended DCBA dose is 75 mg once-monthly.

• As a world-wide operating pharmaceutical company, we are investing in the future of medicine. We develop drugs of high medical value so as to continuously improve the quality of life.

  We make the most of knowledge. Using interdisciplinary networks we build bridges to academic researchers around the world, as well as to highly specialized biotech pioneers and partners in the pharmaceutical industry. We combine our own longstanding medical and pharmaceutical expertise with the latest discoveries from genomic research. Throughout, our research focuses on a meaningful combination of early diagnosis, prevention, treatment and therapy control.

See also the Pfizer example.

Back to How to become a sponsor.